Alfred Lee, MD, PhD
Professor of Medicine (Hematology)Cards
About
Research
Publications
2025
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
Siegal D, Tseng E, Schünemann H, Angchaisuksiri P, Cuker A, Dane K, DeSancho M, Diuguid D, Griffin D, Klok F, Lee A, Neumann I, Pai A, Righini M, Sanfilippo K, Terrell D, Akl E, Al Jabiri R, Al Jabiri Y, Barbara A, Bognanni A, Akl I, Boulos M, Brignardello-Petersen R, Chan M, Charide R, Colunga-Lozano L, Dearness K, Darzi A, Hussein H, Karam S, Kolb P, Mansour R, Morgano G, Morsi R, Muti-Schünemann G, Nadim M, Noori A, Philip B, Piggott T, Qiu Y, Benitez Y, Schünemann F, Stevens A, Solo K, Wiercioch W, Mustafa R, Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances 2025, 9: 1247-1260. PMID: 39437797, DOI: 10.1182/bloodadvances.2024014219.Peer-Reviewed Original ResearchConceptsCOVID-19-related critical illnessConditional recommendationAcute illnessHealth care professionalsAmerican Society of HematologyProphylactic-intensity anticoagulationCritical illnessEvidence-based recommendationsVenous thromboembolismRandomized controlled trialsCare professionalsPatient representativesRisk of venous thromboembolismGuideline developmentRecommendations AssessmentTherapeutic-intensity anticoagulationExecutive summaryLiving guidelinesMultidisciplinary panelIncreased risk of venous thromboembolismSystematic reviewAssessed certaintyCOVID-19-relatedControlled trialsMcMaster UniversityIntercontinental variations in the presentation and management of venous thromboembolism
Chaar C, Chan S, Lee A, Bikdeli B, Tiberio G, Chopard R, Weinberg I, Yamashita Y, Nikandish R, Monreal M. Intercontinental variations in the presentation and management of venous thromboembolism. JVS-Vascular Insights 2025, 3: 100201. DOI: 10.1016/j.jvsvi.2025.100201.Peer-Reviewed Original ResearchManagement of venous thromboembolismVenous thromboembolismPulmonary embolismLow-risk pulmonary embolismTreatment modalities of patientsOpen pulmonary embolectomyVenous thromboembolism presentationHigh-risk PEIntermediate-risk PELow-molecular-weight heparinLower body mass indexVitamin K antagonistsSystemic thrombolytic therapyProportion of patientsVenous thromboembolism patientsBody mass indexCoronary artery diseaseTreatment of PEPulmonary embolectomyK antagonistsOral anticoagulantsProximal DVTActive cancerOutpatient anticoagulationEndovascular treatment
2024
In-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor
Restrepo-Espinosa V, Lee A, Prozora S, Patel P, Nassiri N. In-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2024, 13: 101997. PMID: 39515753, DOI: 10.1016/j.jvsv.2024.101997.Peer-Reviewed Original ResearchLow-flow vascular malformationsMTOR inhibitorsClinical successVascular malformationsSide effectsLocalized intravascular coagulopathyOral aphthous ulcersKlippel-Trenaunay syndromeLymphatic malformationsVenous malformationsRe-interventionDelayed complicationsNon-syndromicTechnical successAphthous ulcersIntravascular coagulopathyD-dimerEndovascular treatmentSystemic exposureAdjunctive therapySystemic toxicityFrequent bloodMalformationsSelf-limitingMTOR inhibitionUse of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
Stempel J, Wang R, Lee A, Ma X, Podoltsev N. Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database. Blood 2024, 144: 2319. DOI: 10.1182/blood-2024-202185.Peer-Reviewed Original ResearchHorse anti-thymocyte globulinLow transfusion burdenAcquired aplastic anemiaCalcineurin inhibitor levelsCalcineurin inhibitorsSevere AARed blood cellsEltrombopag therapyTransfusion burdenMedian proportion of daysTransfusion of red blood cellsCalcineurin inhibitor agentsMedian starting doseAnti-thymocyte globulinDiagnosis to initiationTransplant-ineligible patientsBone marrow failureRare autoimmune disorderReduce transfusion requirementsBaseline red blood cellRetrospective cohort studyStudent's t-testProportion of daysBlue Cross Blue ShieldElixhauser comorbidity scoreCost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 2024, 145: 127-140. PMID: 39374533, PMCID: PMC11738035, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcomeGuide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice
Dizman N, Bakouny Z, Haykal T, Riano I, Desai A, Butt A, Basu A, Zhao D, Saad E, Saliby R, Gosain R, Gosain R, Ardeshir F, Deng L, Matt-Amaral L, Arnaoutakis K, Bekaii-Saab T, Manochakian R, Marshall A, Forde P, Murphy M, Subbiah V, Chavez-MacGregor M, Owonikoko T, Lopes G, Aggarwal C, Lee A, Choueiri T. Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. JCO Oncology Practice 2024, 21: 292-299. PMID: 39374449, DOI: 10.1200/op-24-00565.Peer-Reviewed Original ResearchInternational medical graduatesOncology workforceMedical graduatesContribution of international medical graduatesDiverse population of patientsOncology professionalsHematology/oncology fellowsUnited StatesFellowship trainingDiverse populationsMedical oncologyGreater awarenessPopulation of patientsWorkforceOncologyPracticing oncologistsSignificant hardshipASCOEarly career positionsUnique challengesCareer positionsHigh-qualityCommunities of practiceAwarenessCommunityEvaluating the impact of a year-long external mentorship pilot program in classical hematology
Qureshy Z, Nair P, Vesely S, King A, Lee A, Connell N, von Drygalski A, Wong-Sefidan I, Murphy M, Mistry R, Zon R, Reid E, Fritz J, Park S. Evaluating the impact of a year-long external mentorship pilot program in classical hematology. Blood Advances 2024, 8: 4833-4844. PMID: 39087874, PMCID: PMC11416643, DOI: 10.1182/bloodadvances.2024013218.Peer-Reviewed Original ResearchConceptsMentorship programMixed-methods sequential explanatory designScholarly projectsPerceived positive impactSequential explanatory designFocus groupsHematology/oncology fellowsMentee focus groupMedical education institutionsPilot programMentorship opportunitiesMentor respondentsEffective mentorshipMedical oncologyExplanatory designMentor surveysFaculty mentorsMentee perceptionsMentorshipProfessional identityMenteesPhenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityFactor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease
Allen C, Heskel M, Butt A, Tormey C, Pine A, Lee A, Gautam S. Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. Acta Haematologica 2024, 148: 220-225. PMID: 39004080, DOI: 10.1159/000540239.Peer-Reviewed Original ResearchISTH DIC scoreFactor VIII levelsArea under the curveDIC scoreLiver diseaseFactor VIIIRetrospective chart review of patientsChart review of patientsCoagulopathy of liver diseaseReview of patientsRetrospective chart reviewCalculate area under the curveReceiver operating characteristic curveMultiple logistic regressionISTH scoreLaboratory parametersClinical challengeClinical utilityPatientsCharacteristic curveLab variablesLogistic regressionLiverDiseaseDiagnostic toolLongitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program
Srikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program. EMJ Oncology 2024, 1: 37-39. DOI: 10.33590/oncolamj/zgwb5064.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Alfred Ian Lee, MD, PhD, is Professor of Medicine (Hematology) and Program Director for the hematology/oncology fellowship program. He received his MD/PhD from the Yale School of Medicine in 2004. Dr. Lee completed residency in internal medicine at Brigham & Women’s Hospital, where he served as Chief Medical Resident, followed by a fellowship in hematology/oncology at Dana-Farber Cancer Institute. His primary academic interests are classical hematology, thrombosis, and medical education.
He has received such honors as the Charles W. Bohmfalk Prize for teaching in the basic sciences, the Leah M. Lowenstein Award for excellence in the promotion of humane and egalitarian medical education, the Yale Cancer Center Award for Mentorship Excellence, and the David J. Lefell Prize for Clinical Excellence.
Clinical Specialties
Hematology; Hematology & Oncology
Fact Sheets
Hereditary Hemorrhagic Telangiectasia (HHT)
Learn More on Yale MedicineBleeding Disorders
Learn More on Yale MedicineHodgkin's Lymphoma
Learn More on Yale MedicineAnemia
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- February 06, 2025Source: Medscape
Compassion Fatigue: How Oncologists Can Recognize the Signs
- June 12, 2024
Yale Medical Oncology-Hematology Fellowship Graduation 2024
- May 28, 2024
Annual Fellows Research Day 2024
- May 20, 2024
American Society of Hematology Selects Jennifer Afranie-Sakyi, MD to Receive the 2024 ASH Minority Hematology Fellow Award
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.